My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 124

    1.

    Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.

    Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk C, Tarnow L, Parving HH.

    Diabetes. 2006 Dec;55(12):3550-5.PMID: 17130503 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study.

    Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk CG, Tarnow L, Parving HH.

    Scand J Clin Lab Invest. 2008;68(8):731-8.PMID: 18609080 [PubMed - indexed for MEDLINE]Related articles

    3.

    Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria.

    Andersen S, Bröchner-Mortensen J, Parving HH; Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group.

    Diabetes Care. 2003 Dec;26(12):3296-302.PMID: 14633817 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

    Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.

    N Engl J Med. 2001 Sep 20;345(12):870-8.PMID: 11565519 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]

    Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S, Arner P.

    Ugeskr Laeger. 2001 Oct 1;163(40):5519-24. Danish. PMID: 11601118 [PubMed - indexed for MEDLINE]Related articles

    6.

    [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy]

    Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H.

    Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1721-6. German. PMID: 16868875 [PubMed - indexed for MEDLINE]Related articles

    7.

    Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Fassi R, Fogari R.

    Clin Ther. 2007 Apr;29(4):602-10.PMID: 17617283 [PubMed - indexed for MEDLINE]Related articles

    8.

    Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study.

    Sasso FC, Carbonara O, Persico M, Iafusco D, Salvatore T, D'Ambrosio R, Torella R, Cozzolino D.

    Diabetes Care. 2002 Nov;25(11):1909-13.PMID: 12401731 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.

    Palmer AJ, Roze S, Valentine WJ, Ray JA, Frei A, Burnier M, Hess B, Spinas GA, Brändle M.

    Swiss Med Wkly. 2006 May 27;136(21-22):346-52.PMID: 16779715 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting]

    Lehnert H, Bramlage P, Pittrow D, Kirch W.

    MMW Fortschr Med. 2003 Oct 9;145 Suppl 3:81-7. German. PMID: 15490772 [PubMed - indexed for MEDLINE]Related articles

    11.

    Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.

    Busch M, Franke S, Wolf G, Rohde RD, Stein G; Collaborative Study Group.

    Nephron Clin Pract. 2008;108(4):c291-7. Epub 2008 Apr 24.PMID: 18434751 [PubMed - indexed for MEDLINE]Related articles

    12.

    Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.

    Cetinkalp SS, Karadeniz MM, Erdogan MA, Ozgen GA, Yilmaz CO.

    Saudi Med J. 2008 Oct;29(10):1414-8.PMID: 18946564 [PubMed - indexed for MEDLINE]Related articles

    13.

    Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

    Palmer AJ, Valentine WJ, Ray JA.

    Int J Clin Pract. 2007 Oct;61(10):1626-33. Review.PMID: 17877649 [PubMed - indexed for MEDLINE]Related articles

    14.

    How different urinary albumin excretion rates can predict progression to nephropathy and the effect of treatment in hypertensive diabetics.

    Llewelyn DE, Garcia-Puig J.

    J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):141-5.PMID: 15526250 [PubMed - indexed for MEDLINE]Related articles

    15.

    Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.

    Palmer AJ, Rodby RA.

    Kidney Int Suppl. 2004 Nov;(92):S118-20. Review.PMID: 15485404 [PubMed - indexed for MEDLINE]Related articles

    16.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    17.

    Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.

    Palmer AJ, Annemans L, Roze S, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, De Alvaro F.

    Kidney Int Suppl. 2005 Jan;(93):S52-4.PMID: 15613069 [PubMed - indexed for MEDLINE]Related articles

    18.

    Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxidative stress and adhesion molecules in patients with persistent atrial fibrillation.

    Goette A, D'Alessandro A, Bukowska A, Kropf S, Mewis C, Stellbrink C, Tebbenjohanns J, Weiss C, Lendeckel U.

    Clin Drug Investig. 2008;28(9):565-72.PMID: 18666803 [PubMed - indexed for MEDLINE]Related articles

    19.

    Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study.

    Rossing K, Christensen PK, Andersen S, Hovind P, Hansen HP, Parving HH; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study.

    Diabetes Care. 2003 Mar;26(3):569-74.PMID: 12610003 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Prevention and treatment of diabetic nephropathy: the program for irbesartan mortality and morbidity evaluation.

    Ravera M, Ratto E, Vettoretti S, Parodi D, Deferrari G.

    J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S48-52. Review.PMID: 15938034 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity